Oramed Pharmaceuticals buy geldnutzer
Start price
19.06.14
/
50%
€7.03
Target price
19.12.14
€11.45
Performance (%)
-34.55%
End price
19.12.14
€4.60
Summary
This prediction ended on 19.12.14 with a price of €4.60. The BUY prediction by geldnutzer for Oramed Pharmaceuticals performed very badly with a performance of -34.55%. geldnutzer has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oramed Pharmaceuticals | -1.464% | -1.464% | -12.404% | -72.987% |
| iShares Core DAX® | 1.662% | 4.835% | 17.361% | 19.329% |
| iShares Nasdaq 100 | 0.667% | 0.000% | 38.234% | 55.157% |
| iShares Nikkei 225® | -2.139% | -4.786% | 13.099% | 7.393% |
| iShares S&P 500 | 0.564% | 0.775% | 29.181% | 46.527% |
Comments by geldnutzer for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Kommt die Diabetes-Pille kennt der Kurs nur eine Richtung.
Ich bin durch Zufall auf diese Aktie gestossen, kann deshalb nachvollziehen, warum der Kurs und die Aussichten der Mitglieder so weit aus einander liegen. Ich werde hier mal sehen was geht.
(Laufzeit überschritten)